02235 MICROTECH MED-B
- 4.030
- -0.100-2.42%
MICROTECH MED-B News
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
微泰醫療-B：2023年年度報告
Without piercing fingers and without sensing sugar, Weitai Medical released a new blood sugar meter
Repurchase Collection on April 9 | Tencent Holdings, HSBC Holdings, etc. bought back one after another, of which Tencent Holdings spent HK$1,001 billion
According to documents disclosed by the Hong Kong Stock Exchange on April 10, $Tencent Holdings (00700.HK) $ and $HSBC Holdings (00005.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 3.28 million common shares on April 9, involving an amount of HK$1,001 billion. The repurchase price per share ranged from HK$308.2 to HK$303. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 202 million shares, accounting for 2.111% of the number of shares issued when the ordinary resolution was passed. ② $HSBC Holdings (0000
Weitai Medical-B (02235.HK) spent HK$126,800 to buy back 31,800 shares on April 9
Gelonghui, April 9, 丨 Weitai Medical-B (02235.HK) issued an announcement. On April 9, 2024, it spent HK$126,800 to repurchase 31,800 shares at a repurchase price of HK$3.92-4.1 per share.
Weitai Medical-B (02235.HK) obtained CDBI Partners Fund II, L.P. OTC to increase its holdings of 3 million H shares worth approximately HK$12.03 million
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, CDBI Partners Fund II, L.P., increased its OTC holdings of $WeChat Medical-B (02235.HK) by $3 million on March 28 at an average price of HK$4.01 per share, worth about HK$12.03 million. After the increase in holdings, CDBI Partners Fund II, L.P. recently held a total of 10.026,200 shares, and the good position ratio increased from 4.04% to 5.76%. This transaction involves other related parties: CD Capit
March 28 repurchase collection | Tencent Holdings, HSBC Holdings, etc. have repurchased, of which Tencent Holdings spent HK$1.03 billion
According to documents disclosed by the Hong Kong Stock Exchange on April 2, $Tencent Holdings (00700.HK) $ and $HSBC Holdings (00005.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 3.28 million common shares on March 28, involving an amount of HK$1,003 billion. The repurchase price for each share ranged from HK$308.6 to HK$301.8. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 186 million shares, accounting for 1.941% of the number of shares issued when the ordinary resolution was passed. ② $HSBC Holdings (00
Weitai Medical-B (02235) spent about HK$116,600 to buy back 28,200 shares on March 28
Weitai Medical-B (02235) announced that it will spend about HK$116,600 to return it on March 28, 2024...
Weitai Medical-B (02235): Shi Yonghui was appointed as Joint Company Secretary
According to the Zhitong Finance App, Weitai Medical-B (02235) announced that Shi Yonghui has been appointed as the company's joint company secretary for a period of 3 years from March 27, 2024. Zhu Bimin, the sole company secretary of Dr. Shi, was appointed to continue as the other joint company secretary.
Weitai Medical-B (02235) released annual results and achieved a year-on-year increase of 45.86% in revenue of 253 million yuan
According to the Zhitong Finance App, Weitai Medical-B (02235) announced its annual results for the year ended December 31, 2023. The group achieved operating income of 253 million yuan (RMB, same below) during the period, an increase of 45.86%; gross profit of 126 million yuan, an increase of 53.45%; and R&D expenses of 70.984 million yuan, an increase of 14.75% year on year. According to the announcement, the increase in earnings was mainly due to the rapid growth of AideX's continuous glucose monitoring system, the steady growth of the Equil adhesive insulin pump system, and the rapid growth of the blood sugar monitoring system. This increase was affected by
MICROTECH MED-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Weitai Medical-B (02235.HK) plans to hold a board meeting on March 27 to consider and approve the annual results
Gelonghui March 15 | Weitai Medical-B (02235.HK) announced that a board meeting will be held on March 27, 2024 (Wednesday), which includes reviewing and approving the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and considering a proposal to pay a final dividend (if any).
MICROTECH MED-B: NOTICE OF BOARD MEETING
Financial Services Association Venture Capital Connect: In February, the domestic medical sector raised 4.1 billion yuan, down 42% month-on-month, with the highest amount of financing for innovative drugs
In February 2024, there were 80 private equity financing incidents in the domestic healthcare sector, a decrease of 27% from the previous month; the total amount of disclosed financing was about 4,066 billion yuan, a decrease of 42% from the previous month.
March 1 repurchase collection | HSBC Holdings, AIA and others bought back, of which HSBC Holdings spent HK$176 million
According to documents disclosed by the Hong Kong Stock Exchange on March 4, $HSBC Holdings (00005.HK) $ and $AIA (01299.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 2,904,400 common shares on February 29, involving an amount of HK$176 million. The repurchase price for each share ranged from HK$60.8 to HK$60.2. ② $AIA (01299.HK) $ repurchased 2,643 million common shares on March 1, involving an amount of HK$165 million. The repurchase price per share ranged from HK$63.15 to HK$61.75
Weitai Medical-B (02235): Duobo Resigns as Joint Company Secretary
According to the Zhitong Finance App, Weitai Medical-B (02235) issued an announcement. Duobo has proposed to resign as the company's joint company secretary, effective February 29, 2024.
Repurchase Collection on February 23 | AIA, Kuaishou-W, etc. bought back one after another, of which AIA Insurance cost HK$110 million
According to documents disclosed by the Hong Kong Stock Exchange on February 26, $AIA (01299.HK) $, $Kuaishou-W (01024.HK) $, etc. repurchased shares. ① $AIA (01299.HK) $ repurchased 1.7 million common shares on February 23, involving an amount of HK$110 million. The repurchase price for each share ranged from HK$65.5 to HK$64.4. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 300 million shares, accounting for 2.581% of the number of shares issued when the ordinary resolution was passed. ② $Kuaishou-W (01024.HK
Weitai Medical-B (02235.HK) spent HK$151,000 to buy back 36,200 shares on February 23
Gelonghui, Feb. 23 | Weitai Medical-B (02235.HK) announced that on February 23, it spent HK$151,000 to repurchase 36,200 shares at a price of HK$4-4.25 per share.
Repurchase Collection on February 22 | Yum China, Kuaishou-W, etc. bought back one after another, of which Yum China spent HK$36.6715 million
According to documents disclosed by the Hong Kong Stock Exchange on February 23, $Yum China (09987.HK) $, $Kuaishou-W (01024.HK) $, etc. repurchased shares. ① $Yum China (09987.HK) $ repurchased 104,800 common shares on February 21, involving an amount of HK$36.6715 million. The repurchase price per share ranged from HK$334.2 to HK$321.2. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 1,067,000 shares, accounting for 0.24% of the number of shares issued when the ordinary resolution was passed. ② $
Weitai Medical-B (02235.HK) spent HK$144,700 to buy back 35,600 shares on February 22
Gelonghui, Feb. 22丨Weitai Medical-B (02235.HK) announced that on February 22, it spent HK$144,700 to repurchase 35,600 shares at a price of HK$4.22-3.8 per share.
Analysis
Price Target
No Data
